Literature DB >> 17167093

Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides.

Ying Li1, Anthony N van den Pol.   

Abstract

The hypocretin/orexin arousal system plays a key role in maintaining an alert wake state. The hypocretin peptide is colocalized with an opioid peptide, dynorphin. As dynorphin may be coreleased with hypocretin, we asked what action simultaneous stimulation with the excitatory neuropeptide hypocretin and the inhibitory peptide dynorphin might exert on cells postsynaptic to hypocretin axons, including hypocretin neurons. Hypocretin neurons received direct synaptic contact from other hypocretin neurons but showed little direct response to hypocretin. Here, we show that mouse hypocretin neurons are acutely sensitive to dynorphin. Dynorphin inhibits the hypocretin system by direct postsynaptic actions (hyperpolarization, decreased spike frequency, increased GIRK (G-protein-gated inwardly rectifying K+ channel) current, and attenuated calcium current, and indirectly by reducing excitatory synaptic tone. Interestingly, a selective antagonist of kappa-opioid receptors enhanced activity of the hypocretin system, suggesting ongoing depression by endogenous hypothalamic opioids. Electrical stimulation of hypothalamic microslices that contained hypocretin cells and their axons evoked dynorphin release. Costimulation with dynorphin and hypocretin had three different effects on neurons postsynaptic to hypocretin axons: direct response to only one or the other of the two peptides [hypocretin cells respond to dynorphin, arcuate neuropeptide Y (NPY) cells respond to hypocretin], differential desensitization causing shift from inhibitory current to excitatory current with repeated coexposure (melanin-concentrating hormone neurons), synergistic direct excitation by hypocretin and presynaptic attenuation of inhibition by dynorphin (arcuate NPY neurons). These results suggest that hypocretin neurons may be able to exercise a high degree of modulatory control over postsynaptic targets using multiple neuropeptides with target-dependent actions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167093      PMCID: PMC6674960          DOI: 10.1523/JNEUROSCI.3380-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Regulation of Lateral Hypothalamic Orexin Activity by Local GABAergic Neurons.

Authors:  Loris L Ferrari; Daniel Park; Lin Zhu; Matthew R Palmer; Rebecca Y Broadhurst; Elda Arrigoni
Journal:  J Neurosci       Date:  2018-01-08       Impact factor: 6.167

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  What optogenetic stimulation is telling us (and failing to tell us) about fast neurotransmitters and neuromodulators in brain circuits for wake-sleep regulation.

Authors:  Elda Arrigoni; Clifford B Saper
Journal:  Curr Opin Neurobiol       Date:  2014-07-26       Impact factor: 6.627

Review 4.  Central functions of the orexinergic system.

Authors:  Xiao-Yang Zhang; Lei Yu; Qian-Xing Zhuang; Jing-Ning Zhu; Jian-Jun Wang
Journal:  Neurosci Bull       Date:  2013-01-08       Impact factor: 5.203

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 6.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

7.  Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal.

Authors:  Hao Huang; Claudio Acuna-Goycolea; Ying Li; H M Cheng; Karl Obrietan; Anthony N van den Pol
Journal:  J Neurosci       Date:  2007-05-02       Impact factor: 6.167

8.  Physiological functions of glucose-inhibited neurones.

Authors:  D Burdakov; J A González
Journal:  Acta Physiol (Oxf)       Date:  2008-10-28       Impact factor: 6.311

9.  Dynorphin inhibits basal forebrain cholinergic neurons by pre- and postsynaptic mechanisms.

Authors:  L L Ferrari; L J Agostinelli; M J Krashes; B B Lowell; T E Scammell; E Arrigoni
Journal:  J Physiol       Date:  2016-01-05       Impact factor: 5.182

10.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.